Logo image of HUMA

HUMACYTE INC (HUMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HUMA - US44486Q1031 - Common Stock

1.25 USD
+0.03 (+2.46%)
Last: 11/24/2025, 2:59:07 PM
Fundamental Rating

2

Overall HUMA gets a fundamental rating of 2 out of 10. We evaluated HUMA against 533 industry peers in the Biotechnology industry. HUMA has a bad profitability rating. Also its financial health evaluation is rather negative. HUMA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HUMA had negative earnings in the past year.
HUMA had a negative operating cash flow in the past year.
In the past 5 years HUMA always reported negative net income.
HUMA had a negative operating cash flow in each of the past 5 years.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

HUMA has a Return On Assets (-42.31%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -1449.19%, HUMA is doing worse than 81.61% of the companies in the same industry.
Industry RankSector Rank
ROA -42.31%
ROE -1449.19%
ROIC N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

HUMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for HUMA has been increased compared to 1 year ago.
HUMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HUMA has been reduced compared to a year ago.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -8.27, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HUMA (-8.27) is worse than 68.48% of its industry peers.
HUMA has a Debt/Equity ratio of 2.97. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HUMA (2.97) is worse than 80.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Altman-Z -8.27
ROIC/WACCN/A
WACCN/A
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.45 indicates that HUMA has no problem at all paying its short term obligations.
HUMA has a Current ratio of 2.45. This is in the lower half of the industry: HUMA underperforms 69.42% of its industry peers.
HUMA has a Quick Ratio of 1.93. This is a normal value and indicates that HUMA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.93, HUMA is doing worse than 75.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 1.93
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.84% over the past year.
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HUMA will show a very strong growth in Earnings Per Share. The EPS will grow by 44.01% on average per year.
HUMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 389.74% yearly.
EPS Next Y72.61%
EPS Next 2Y31.33%
EPS Next 3Y28.13%
EPS Next 5Y44.01%
Revenue Next Year1596.89%
Revenue Next 2Y1531.24%
Revenue Next 3Y630.61%
Revenue Next 5Y389.74%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HUMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

HUMA's earnings are expected to grow with 28.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.33%
EPS Next 3Y28.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HUMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HUMACYTE INC

NASDAQ:HUMA (11/24/2025, 2:59:07 PM)

1.25

+0.03 (+2.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners36.8%
Inst Owner Change-19.74%
Ins Owners6.68%
Ins Owner Change2.24%
Market Cap230.97M
Revenue(TTM)N/A
Net Income(TTM)-58.72M
Analysts81.54
Price Target8.01 (540.8%)
Short Float %21.01%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)99.47%
Min EPS beat(2)-45.54%
Max EPS beat(2)244.48%
EPS beat(4)2
Avg EPS beat(4)51.51%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)11.14%
EPS beat(12)6
Avg EPS beat(12)7.65%
EPS beat(16)9
Avg EPS beat(16)25.7%
Revenue beat(2)0
Avg Revenue beat(2)-51.96%
Min Revenue beat(2)-70.58%
Max Revenue beat(2)-33.34%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.06%
PT rev (3m)-15.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.39%
EPS NY rev (1m)0.49%
EPS NY rev (3m)-36.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-43.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 282.37
P/FCF N/A
P/OCF N/A
P/B 57
P/tB 57
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.31%
ROE -1449.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.45%
Cap/Sales 218.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 1.93
Altman-Z -8.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.4%
Cap/Depr(5y)14.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y72.61%
EPS Next 2Y31.33%
EPS Next 3Y28.13%
EPS Next 5Y44.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1596.89%
Revenue Next 2Y1531.24%
Revenue Next 3Y630.61%
Revenue Next 5Y389.74%
EBIT growth 1Y-4.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.92%
EBIT Next 3Y28.21%
EBIT Next 5Y25.39%
FCF growth 1Y-33.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.24%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 2 / 10 to HUMA.


What is the valuation status of HUMACYTE INC (HUMA) stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


Can you provide the profitability details for HUMACYTE INC?

HUMACYTE INC (HUMA) has a profitability rating of 0 / 10.


Can you provide the financial health for HUMA stock?

The financial health rating of HUMACYTE INC (HUMA) is 2 / 10.